Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

NCT01190410 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: certolizumab pegol
DRUG: certolizumab pegol

Sponsor

UCB Pharma